Course Overview
Repurposed Medications in Oncology: A Study Guide for Doctors (Module 1, Course 5 – Fenbendazole vs. Mebendazole) presents a detailed analysis of these two benzimidazole drugs and their role in cancer therapy. While both have gained attention for their potential anti-cancer properties, this guide highlights why Mebendazole is the superior choice, supported by its clinical trials, broader mechanisms of action, and safer pharmacokinetics.
This course provides an evidence-based breakdown of the key differences, offering oncologists, functional medicine doctors, and researchers a comprehensive look at how these medications work, their effectiveness, and their real-world applications.
Who is This Course For?
- Oncologists and Cancer Researchers
- Integrative and Functional Medicine Doctors
- Medical Students and Healthcare Practitioners
- Pharmacists and Clinical Scientists
What You Will Learn
- The mechanistic differences between Fenbendazole and Mebendazole
- The scientific data supporting Mebendazole’s role in cancer treatment
- The lack of human clinical trials for Fenbendazole and its risks
- The pharmacokinetics, bioavailability, and metabolism of both drugs
- Why Mebendazole is the preferred choice in integrative oncology
- Dosing strategies, toxicity concerns, and safety protocols
Course Structure & Content
- Chapter 1: Repurposing Medications in Oncology
- Chapter 2: History of Mebendazole and Fenbendazole
- Chapter 3: Scientific Research & Clinical Studies Comparison
- Chapter 4: Pharmacokinetics and Bioavailability Differences
- Chapter 5: Mechanisms of Action in Cancer Therapy
- Chapter 6: Drug Interactions and Metabolism Pathways
- Chapter 7: Dosing Strategies and Safety Considerations
- Chapter 8: Toxicity and Side Effects – What You Need to Know
- Chapter 9: Combination Therapy – Stacking with Chemotherapy & Radiation
- Chapter 10: Key Takeaways & Next Steps
- Chapter 11: Self-Guided Quiz for Medical Professionals
- Chapter 12: FAQ – Addressing Common Questions





Reviews
There are no reviews yet.